Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01352286 · OUTCOME

Best Objective Response (BOR)

Redirected Auto T Cells for Advanced Myeloma · Source last updated 2019-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Best Objective Response prior to initiation of lenalidomide and at Year 1

What was measured

Number of participants with Best Objective Response of sCR, CR, VGPR, or PR

Analysis population: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT with Best Objective Response (BOR) data.

Groups in this outcome

NYESO-1ᶜ²⁵⁹T Cells

Participants who received NYESO-1ᶜ²⁵⁹T following ASCT

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
NYESO-1ᶜ²⁵⁹T Cells25

Reported measurements

Prior to Initiation of Lenalidomide : sCR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells1Not reportedNot reportedNot reportedNot reported
Prior to Initiation of Lenalidomide : CR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells0Not reportedNot reportedNot reportedNot reported
Prior to Initiation of Lenalidomide : VGPR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells12Not reportedNot reportedNot reportedNot reported
Prior to Initiation of Lenalidomide : PR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells7Not reportedNot reportedNot reportedNot reported
Year 1 : sCR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells2Not reportedNot reportedNot reportedNot reported
Year 1 : CR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells1Not reportedNot reportedNot reportedNot reported
Year 1 : VGPR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells13Not reportedNot reportedNot reportedNot reported
Year 1 : PR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
NYESO-1ᶜ²⁵⁹T Cells5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Prior to Initiation of Lenalidomide : sCR
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Prior to Initiation of Lenalidomide : CR
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        12
    title
    Prior to Initiation of Lenalidomide : VGPR
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Prior to Initiation of Lenalidomide : PR
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Year 1 : sCR
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Year 1 : CR
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        13
    title
    Year 1 : VGPR
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        5
    title
    Year 1 : PR
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Number of participants with Best Objective Response of sCR, CR, VGPR, or PR
groups
  1. description
    Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
    id
    OG000
    title
    NYESO-1ᶜ²⁵⁹T Cells
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT with Best Objective Response (BOR) data.
reporting Status
POSTED
time Frame
Best Objective Response prior to initiation of lenalidomide and at Year 1
title
Best Objective Response (BOR)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice